



Intravenous Immunoglobulin Resistant Kawasaki Disease

Mohammad Reza Navaeifar¹

Mohammad Sadegh Rezai^{2*}

¹Nosocomial Infection Research Centre, Mazandaran University of Medical Sciences, Sari, Iran

²Department of Pediatric Infectious Disease, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

ARTICLE INFO

Article type:

Review Article

Article history:

Received: 23 Apr 2012

Revised: 17 Jul 2012

Accepted: 12 Jan 2013

Keywords:

Intravenous Immunoglobulin,
Resistant, Kawasaki Disease

<http://jpr.mazums.ac.ir>

ABSTRACT

Kawasaki disease is a systemic vasculitis that mainly affects younger children. Although the definite cause still remains unknown but the clinical and epidemiologic findings discuss an infectious cause. The prevalence of incomplete Kawasaki disease reported 15 to 36.2%, and it is more frequent in the extremes of the age spectrum. Non delayed treatment of disease should be initiated because of critical cardiac vascular complications. Up to 15% - 25% of patients with Kawasaki disease who remain febrile after administration of first dose of intravenous immunoglobulin plus aspirin are classified as refractory disease. These intravenous immunoglobulin resistant cases are at increasing risk for coronary artery complications. The strategy on prediction of potentially non responder and treatment of intravenous immunoglobulin resistant patients is now controversial but some useful points were recommended.

Introduction

Kawasaki disease (KD) is a systemic vasculitis that mainly affects children younger than five years old.¹ Although the clinical and epidemiologic findings discuss an infectious cause, the definite cause still remains unknown. Some studies found genetic and familial tendency to KD.²⁻⁴ However, the exact genetic factors are not yet detected and no obvious genetic risk factor is found for coronary artery lesion (CAL) in KD.⁵

Up to 75% - 85% of patients with KD become afebrile after administration of single dose of intravenous immunoglobulin (IVIG) plus aspirin. Some believe that IVIG-resistant or refractory KD require additional treatments to prevent increasing risk for coronary artery lesion (CAL).⁶⁻⁸ Increased

diagnosis of KD revealed high incidence of refractory KD.⁹⁻¹¹

KD still remains the major cause of acquired children heart disease in developed countries.¹² CAL is the most serious complication of KD that includes coronary artery aneurysm, myocardial infarction, coronary artery fistula and coronary artery dilatation.¹³ Theoretically identifying potentially refractory KD or high risk patients at the time of diagnosis might lead to treat high risk KD with combination of adjunctive therapy such as Corticosteroid or TNF α antagonist added to IVIG in initial treatment.

*Corresponding Author: Mohammad Sadegh Rezai MD, Assistant professor of pediatric infectious diseases

Mailing Address: Department of Pediatric Infectious Disease, Bou Ali Sina Hospital, Pasdaran Boulevard, Sari, Iran.

Tel: +98 151 2233011-15

Fax: +98 151 2234506

Email: drmsrezaei@yahoo.com

Diagnosis

According to the American Heart Association (AHA), the clinical manifestation of typical KD are fever for more than five days and at least four of the following: bilateral bulbar conjunctival injection without exudates, mucocutaneous changes of oropharynx and lips, polymorphous rashes, changes in peripheral extremities and cervical lymph node enlargement (greater than 1.5cm) and exclusion of other similar diseases.^{14,15} Another diagnostic guideline for KD published by Japanese KD research committee that has 6 optional principal signs includes fever for more than five days, bilateral bulbar conjunctival injection, changes in lips and oral cavity, polymorphous exanthema, changes in peripheral extremities and enlargement of cervical lymph node (without defined size).¹⁶

Atypical and Incomplete KD

It seems complete and incomplete KD are situated on two sides of a continuous spectrum.¹⁷

“Atypical KD” and “incomplete KD” has been used for nomination of cases with incomplete presentation of the disease. But recently proposed that the term “Atypical KD” should be used for those who present unusual complication of KD, such as: lung infiltration or renal failure.¹⁸⁻²¹

Within the KD cases, incomplete KD prevalence reported 15 to 36.2%^{18,19,21-26} and it is more frequent in the extremes of the age spectrum (≤ 1 years old, or ≥ 5 to 9 years old).^{19,21}

Because of more complications in delayed diagnosed KD, especially in coronary artery, the AHA and Japanese Ministry of Health published a criteria for incomplete KD in children ≥ 6 month of age. Both of these criteria suggest CAL in echocardiogram as a principal point. In the criteria established by AHA, fever must continue for at least 5 days and 2 or 3 of five optional signs must be presented²⁷ and in the Japanese criteria four of six principal criteria must be presented.¹⁶

An additional diagnostic algorithm recommended by the AHA for incomplete KD consists of six laboratory and three supporting echocardiographic points (Table 1).

Treatment

Non delayed treatment of KD should be initiated because of critical cardiac vascular complications, even if the diagnosis is not exactly definite.²⁷

The most recommended initial therapy is Aspirin and IVIG during the first 10 days of signs.^{13,27} CAL frequently will happen if therapy is delayed, however, therapy should start at any time if the first 10 days are missed.²⁷

Aspirin: The first medication is aspirin and should be used in anti-inflammatory high dose (80-100 mg/kg/day)⁶ or more often in Japan and Eastern Asia- anti-inflammatory low dose (30-50 mg/kg/day)²⁸ within febrile phase and usually reduces to anti platelet dose (3-5mg/kg/day) after the acute febrile phase and continue until laboratory results return to normal range, unless CAL is detected, although some studies reported that aspirin in acute phase of KD could not improve the IVIG response, fever period or CAL incidence.²⁹ Chemical hepatitis, transient hearing loss, Reye syndrome are the most common side effect of Aspirin. It is noted that Ibuprofen could antagonize the anti-platelet function of low dose Aspirin.^{27,30}

IVIG: Other necessary medication in acute phase of KD is high dose of IVIG (2g/Kg/single dose) that is shown to be useful for decreasing the CAL.²⁷ Although treating with aspirin plus IVIG could reduce the risk of CAL in approximately 85-95% of cases. Some studies report 15-25% of continued fever after this medications and a possibility of CAL. From the first administration of IVIG its dosage was changed and it was revealed that IVIG helps in reducing the symptoms, but CAL increased by elevation of IVIG dose up to 2g/kg.^{31,32}

The most prevalent side effect of IVIG are rash, fever, nausea, hypotension, high solute load, over volume of intravascular fluid, hemolysis, headache and potential risk for transmission of blood borne pathogen.

Steroids: Glucocorticoids newly revised in adjunctive treatment of KD¹⁶ especially in the cases expected to resist IVIG plus aspirin therapy in conditions of relapsed or refractory KD.^{33,34} Although a report by Kato et al⁶⁵ showed that steroids might worsen CAL, later trials noted benefit

Table 1. additional laboratory and echocardiographic points for diagnosis of incomplete KD ²⁷

Additional laboratory points (more than 3 positive points support the diagnosis of KD)

1. Serum Albumin ≤ 3 g/dl
2. Anemia for age
3. Elevation of Alanine aminotransferase
4. Platelets after 7 days ≥ 450000 /mm³
5. WBC ≥ 15000 /mm³
6. Urine WBC ≥ 10 /HPF

Additional echocardiographic points (any of these 3 points support the diagnosis of KD)

- 1- Z score of LAD or RCA ≥ 2.5
- 2- Coronary artery aneurism (by Japanese Ministry of Health Criteria)
 - internal lumen diameter:
 - >3 mm in children < 5 yr.
 - >4 mm in children > 5 yr.
 - of a segment measures ≥ 1.5 times that of an adjacent segment
 - Clearly irregular coronary lumen
- 3- Three of the following:
 - perivascular brightness of coronary artery(CA)
 - lack of tapering of CA
 - decreased LV function
 - mitral regurgitation
 - pericardial effusion
 - Z score in LAD or RCA of 2 to 2.5

LCA: Left coronary artery

RCA: Right coronary artery

CA: coronary artery

LV: Left ventricle

HPF: High power field

Yr: years old

of cortons administered in primary treatment of KD ^{33,36,37}

Dose and prescription of Glucocorticoids vary in different trials recently intravenous pulse methylprednisolone 30mg/kg for one to three days is used with or without consequence oral prednisolone. Another regimen is oral prednisolone 2-3 mg/kg for two weeks followed by 1.5 mg/kg for the next 2 weeks . ^{33,37}

Common early onset complication of Glucocorticoids is hypertension, bradycardia, hypothermia, thrombosis, femoral head necrosis, convulsion, secondary infection, gastrointestinal bleeding, hyperglycemia, hyponatremia and hyperkalemia.

Because of markedly increase of TNF α in KD, especially in patients who develop CAL, researchers try to show whether the TNF- α inhibitors such as infliximab reduce the complications of KD or eliminate its activity. Some studies mentioned some

benefits like elimination of fever and C reactive protein (CRP) level but it did not have the same effect on CAL . ^{38,40} The major side effects of infliximab are anaphylaxis and immunosuppression and the minor side effects are included headache, nausea and upper respiratory tract infections.

Miura et al and Eberhard et al found that infiltration of CD8+ T cells around the affected artery was increased in CAL followed by KD . ⁴¹For this reason they used calineurin inhibitors such as Cyclosporine A and Tacrolimus used for adjunctive therapy of KD . ^{8,42}

Major unwanted effects of cyclosporine A include hepatotoxicity, nephrotoxicity, hypertension, seizure, and electrolyte imbalance.

Plasmapheresis and plasma exchange are other medical treatments that shown could lead to dramatic response but technical difficulties and hazards limits using this therapeutic only for patients resisting other available regimen. ⁴³

Other medical interventions such as pentoxifylline, Ulinastatin, Abciximab, Cyclophosphamide⁴⁴, Methotrexate⁴⁵ and Etanerceptare used to treat KD. Limited studies exist regarding using these agents, but these medications could be considered in treating unresponsive KD. Harada et al used Heparin (15-20 units/kg/hour) in combination with intravenous methylprednisolone (IVMP) to prevent thromboembolic events.⁴⁶ Dipyridamole and clopidogrel as antiplatelet, warfarin and low-molecular-weight heparin as anticoagulant and statins are also used as protection against ongoing atherosclerosis.⁴⁷

Resistance and Relapse

Patients with refractory KD remain febrile within 48 hours of receiving 1 dose of IVIG or have recrudescence of fever after 48 hours of IVIG therapy.⁶

Different centers reported resistance to initial treatment with IVIG from 9.4% up to 38%. Recent studies indicated a relationship between some laboratory and demographic characteristics for identifying refractory KD, such as: age, sex, pretreatment illness duration, initial abnormal echocardiographic results, levels of ESR, CRP, sodium, lactate dehydrogenase, albumin, alanine aminotransferase, percentage of hemoglobin, eosinophil, neutrophil, lymphocyte, band cell, platelet count, and T-Cell activity (Table 2).⁴⁸⁻⁵²

Delayed treatment or resistance to initial therapy more frequently lead to CAL. Usually the Japanese ministry of health criteria or American heart association criteria is used for defining CAL.²⁷

Kobayashi et al⁹ reviewed thirteen variables in KD patients including: duration of illness at initial treatment, gender, age in months, neutrophils percentage in white blood cells, platelet count, aspartate (AST) and alanine (ALT) aminotransferase, total bilirubin, sodium, chloride, total protein, albumin and C-reactive protein(CRP). This multicenter study reviewed 546 cases of KD, retrospectively to develop their predictive model and 204 cases prospectively to test the accuracy of prediction. Initial treatment included IVIG (1g/kg for two consecutive days), aspirin

(30mg/kg/day) and dipyridamole (2mg/kg/day). IVIG non responder is defined as someone who has fever after 24 hours from initial therapy or has recrudescence of fever after an afebrile period. Sensitivity and specificity of initial created scoring model in accuracy tester group was 90% and 77%, respectively. Then they constructed further simplified scoring model using both groups' data and suggested: 2 points for sodium ≤ 133 , 2 points for days of illness at initial treatment ≤ 4 , 2 points for AST ≥ 100 IU/L, 2 points for neutrophils $\% \geq 80$, 1 point for CRP ≥ 10 mg/dl, 1 point for age ≤ 12 months, 1 point for platelet count $\leq 300000/\text{mm}^3$. According to these scoring, low risk strata was sum of points 0 to 3, high risk strata was between 3 to 7, and the score ≥ 7 was considered very high risk. The occurrence of IVIG nonresponder was 75%, 43% and 5% in the very high risk, high risk and low risk group, respectively and the occurrence of CAL was 36%, 16% and 1% in the very high risk, high risk and low risk group, respectively.

The occurrence of IVIG nonresponder was 75%, 43% and 5% in the very high risk, high risk and low risk group, respectively and the occurrence of CAL was 36%, 16% and 1% in the very high risk, high risk and low risk group, respectively.

Sleeper et al⁴⁸ carried out a randomized double blind, placebo-controlled trial of added intravenous methyl prednisolone (IVMP; 30mg/kg in 2-3 hours) to the standard primary treatment of KD (IVIG; 2g/kg and aspirin; 80-100mg/kg) in North America. They compared the Kobayashi, Egami and Sano published risk score for prediction of response to IVIG treatment in a population in North America. The Kobayashi score provide a significant predictor of coronary artery (CA) size changes at 1 and 5 weeks in the subjects not receiving primary steroid therapy. But Egami and Sano scores were not associated with CA size.

Primary steroid therapy in the group who were retreated only with IVIG reduced CA abnormality compared with those who did not receive steroid in primary KD treatment. However, there is not enough evidence regarding the benefits of adjuvant therapy in high or low risk cases. However, there is not enough evidence regarding the benefits of adjuvant therapy in high or low risk cases. However, there is not enough evidence regarding the benefits

Table 2. Scoring suggested by studies for prediction of High risk or Non-responder KD

Author(s)	Year/ Location	Detail/ Number of cases	Point	Value	Suggested Scoring	Sensitivity%	Specificity%	Neg. Pred. Val%	Pos. Pred. Val%
Kobayashi et al ⁹	Korea 2000 to 2006	Retrospective (546 cases) and prospective (204 cases)	sodium	≤133	2 points	very high risk : score ≥7 high risk: 6 ≥ score ≥4 low risk: score ≤3	86	67	
			days of illness at initial treatment	≤4	2 points				
			AST	≥100 IU/L	2 points				
			neutrophils%	≥80%	2 points				
			CRP	≥10 mg/dl	1 points				
			age	≤12 months	1 points				
platelet count	≤300000/mm ³	1 points							
Egami et al ⁴⁹	Japan 1998 to 2004	Retrospective (320 cases)	ALT	≥80 IU/L	2 points	high risk: score ≥4 low risk: score ≤3	78	76	96
			age	≤12 months	1 points				
			days of illness at initial treatment	≤4	1 points				
			platelet count	≤300000/mm ³	1 points				
			CRP	≥8 mg/dl	1 points				
Sano et al ⁵⁵	Japan 1999 to 2000	Retrospective (112 cases)	CRP	≥7 mg/dl	1 points	High risk: 2 Points or more	77	86	94
			Total Bilirubin	≥0.9	1 points				
			AST	≥200 IU/L	1 points				
Nakano et al ⁵⁶	Japan 1977 to 1985	Retrospective (78 cases)	Age	<1 yr	-1	High risk: Total Score is Negative Low risk: Total Score is Zero or Positive			
				1-2 yr	0				
				>2 yr	+1				
			CRP (qualitative)	0-1 plus	+2				
				2-4 plus	+1				
				5 plus	0				
				6 plus	-3				
			Platelet count	<30000	-1				
				0	0				
				>30000	+1				

Neg. Pred. Val: negative predict value

Pos. Pred. Val: positive predict value

of adjuvant therapy in high or low risk cases. However, there is not enough evidence regarding the benefits of adjuvant therapy in high or low risk

cases. They found no difference between steroid therapy effects on CAL prevalence in the high and low risk subgroup.

The sensitivity of these three scores for detecting IVIG resistance was low (33%, 42%, 42% for kubayasi, Egami and Sano, respectively) and the specificity was moderate to high (85%, 87%, 87% for kubayasi, Egami and Sano, respectively). This study suggested that using these scoring criteria will show most KD patients who are at low risk, but most patients do not need more observation or additional therapies to reduce the heart complications. The correlation between CA outcomes and the risk level was low. Also, the serum albumin level and male gender are two independent risk factors not included in these three risk scoring systems.

Do et al⁵³ retrospectively evaluated 77 patients with typical KD and reported that other Korean criteria suggested by Kobayashi et al could help in predicting non-responders KD, they also showed that high percentage of neutrophils and low percentage of lymphocytes during the subacute phase of the disease could predict IVIG resistance. Ashouri et al found that presence of serum albumin ≤ 3 mg/dl, band cell $>10\%$ and existence of CAL at diagnosis are significantly more frequent in non-responder cases.⁵⁴

Treatment of refractory KD

A secondary dose of IVIG (1 to 2 g/Kg) is frequently used for treatment of refractory KD.²⁷ But more prolonged period of fever as a symbol of remaining inflammation after this therapy. Several studies showed at least no increase in CAL and more decrease in fever period after treatment with IVIG plus IVMP 30mg/kg for 1 to 3 days.⁵⁷ Four randomized studies that used IVIG plus corticosteroid therapy and aspirin, suggest that this treatment decreased the need for re-treatment with IVIG and did not increase the risk of CAL.⁶

A multicenter randomized, open-label, blinded-end point's trial in Japan added oral corticosteroid (prednisolone 2mg/kg) to IVIG (2g/kg) and aspirin(30mg/kg). It compared the baseline characteristic of 121 cases and found significant decrease in CAL and a more rapid suppression of fever and inflammatory markers. It suggested that adjuvant corticosteroid therapy could reduce the risk of CAL in potentially high risk cases.⁵⁸

Ogata et al⁵⁹ compared additional IVIG(2g/kg) and pulse methyl prednisolone (IVMP, 30mg/kg/day for 3days) therapy in 27 cases of refractory KD in Japan. All patients were treated initially with IVIG (2g/kg) plus aspirin (30 mg/kg/day). They observed a significant improve in fever relief and count of CAL was found to be lower in IVMP group, however, no significant difference was seen in CAL between the groups.

Hashino et al⁵⁷ used a second dose of IVIG (1g/kg) in 35 unresponsive cases (after IVIG 2g/kg plus aspirin (30mg/kg/day). Seventeen patients (6.5%) who did not respond to retried IVIG therapy were divided into two groups to receive the third dose of IVIG (1g/kg) or steroid pulse therapy (methylprednisolone 20mg/kg). This trial found significant shorter period of fever and lower medical costs in steroid group but there was no significant difference in CAL between the groups although transient coronary artery dilatation was detected in the course of therapy.

Miura et al⁴⁶ prospectively evaluated patients who were unresponsive to two subsequent dose of IVIG (2g/kg/dose). These cases received IVMP (30mg/kg/day) for three days, followed by one week of oral prednisolone (1-2 mg/kg/day). This strategy decreased the risk of CAL in refractory KD thereby. Cyclosporine A and tacrolimus as a calcineurin inhibitor were used by Adriana et al⁶⁰ and Suzuki et al⁴² in a demographic and clinical matched data trial. They reported this treatment as a safe and effective therapy for refractory KD.

An alternative therapy in refractory KD is infliximab 5mg/kg^{40, 61, 62} which is reported to be useful in immunologic disorders that are mediated by TN-F α .

Conclusion

The criteria for typical disease is well approved, however, more investigations are needed for determining such criteria for incomplete and atypical KD. After the years the aetiology of KD still remains unknown, therefore the best treatment of KD especially in refractory cases and identifying potentially nonresponder individuals at the time of diagnosis is await for further researches on different races, demographic factors and maybe geographical

regions. In reviewed articles some simple laboratory or demographic points were offered for predicting refractory cases to classic IVIG regimen or high risk patients for development of CAL, such as high serum ALT, low platelet count, low serum sodium, high CRP, low age, high neutrophil percentage and if days of illness at initial treatment are four or less. The aforementioned points are of great benefit, but effective prevention of CAL depends on worldwide and further trials to establish more reliable predictors and more effective treatments.

Currently, aspirin and IVIG are the most recommended therapies for initial treatment of KD. Renunciation of steroids is somewhat troublesome due to having dramatic effect on treatment of other immunologic diseases even in primary treatment of KD. However, more studies should be carried out to prove its safety and finding the best therapeutic dosage. The other mentioned therapeutics reserved for unusual situation such as refractory disease need further investigations regarding their efficacy for the treatment of Kawasaki disease and reducing its complications.

Conflict of Interest

None declared.

Funding/Support

None declared.

References

1. Holman RC, Curns AT, Belay ED, Steiner CA, Schonberger LB. Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. *Pediatrics*. 2003;112(3):495-501.
2. Yanagawa H, Yashiro M, Nakamura Y, Hirose K, Kawasaki T. Nationwide surveillance of Kawasaki disease in Japan, 1984 to 1993. *The Pediatric infectious disease journal*. 1995;14(1):69.
3. Harada F, Sada M, Kamiya T, Yanase Y, Kawasaki T, Sasazuki T. Genetic analysis of Kawasaki syndrome. *American journal of human genetics*. 1986;39(4):537.
4. Uehara R, Yashiro M, Nakamura Y, Yanagawa H. Kawasaki disease in parents and children. *Acta Paediatrica*. 2003;92(6):694-7.
5. Barron K, Silverman E, Gonzales J, St Clair M, Anderson K, Reveille J. Major histocompatibility complex class II alleles in Kawasaki syndrome: Lack of consistent correlation with disease or cardiac involvement. *J Rheumatol*. 1992;19(11):1790.
6. Tremoulet AH, Best BM, Song S, Wang S, Corinaldesi E, Eichenfield JR, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. *The Journal of pediatrics*. 2008;153(1):117-21. e3.
7. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. *The Pediatric infectious disease journal*. 1998;17(12):1144-8.
8. Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, et al. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. *The Pediatric infectious disease journal*. 2008;27(2):155-60.
9. Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. *Circulation*. 2006;113(22):2606-12.
10. Freeman AF, Shulman ST. Refractory Kawasaki disease. *The Pediatric infectious disease journal*. 2004;23(5):463-4.
11. Dominguez SR, Friedman K, Seewald R, Anderson MS, Willis L, Glodé MP. Kawasaki disease in a pediatric intensive care unit: a case-control study. *Pediatrics*. 2008;122(4):e786-e90.
12. Burns JC, Glodé MP. Kawasaki syndrome. *The Lancet*. 2004;364(9433):533-44.
13. Barron K, Shulman S, Rowley A, Taubert K, Myones B, Meissner H, et al. Report of the National Institutes of Health workshop on Kawasaki disease. *J Rheumatol*. 1999;26(1):170-90.
14. Kawasaki T. [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children]. *Arerugi*=[Allergy]. 1967;16(3):178.
15. Association AH. Diagnostic guidelines for Kawasaki disease. *Circulation*. 2001;103(2):335-6.
16. Ayusawa M, Sonobe T, Uemura S, Ogawa S, Nakamura Y, Kiyosawa N, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). *Pediatrics International*. 2005;47(2):232-4.
17. Forsey J, Mertens L. Atypical Kawasaki disease—a clinical challenge. *European journal of pediatrics*. 2012;1-3.

18. Perrin L, Letierce A, Guitton C, Tran TA, Lambert V, Koné-Paut I. Comparative study of complete versus incomplete Kawasaki disease in 59 pediatric patients. *Joint Bone Spine*. 2009;76(5):481-5.
19. Manlhiot C, Christie E, McCrindle BW, Rosenberg H, Chahal N, Yeung RSM. Complete and incomplete Kawasaki disease: two sides of the same coin. *European journal of pediatrics*. 2012;1-6.
20. Yu JJ. Diagnosis of incomplete Kawasaki disease. *Korean Journal of Pediatrics*. 2012;55(3):83-7.
21. Sonobe T, Kiyosawa N, Tsuchiya K, Aso S, Imada Y, Imai Y, et al. Prevalence of coronary artery abnormality in incomplete Kawasaki disease. *Pediatrics International*. 2007;49(4):421-6.
22. Witt MT, Minich LLA, Bohnsack JF, Young PC. Kawasaki disease: more patients are being diagnosed who do not meet American Heart Association criteria. *Pediatrics*. 1999;104(1):e10-e.
23. Barone SR, Pontrelli LR, Krilov LR. The differentiation of classic Kawasaki disease, atypical Kawasaki disease, and acute adenoviral infection: use of clinical features and a rapid direct fluorescent antigen test. *Archives of pediatrics & adolescent medicine*. 2000;154(5):453.
24. Falcini F, Cimaz R, Calabri G, Picco P, Martini G, Marazzi M, et al. Kawasaki's disease in northern Italy: a multicenter retrospective study of 250 patients. *Clinical and experimental rheumatology*. 2002;20(3):421-6.
25. Hsieh YC, Wu MH, Wang JK, Lee PI, Lee CY, Huang LM. Clinical features of atypical Kawasaki disease. *Journal of microbiology, immunology, and infection= Wei mianyugan ran zazhi*. 2002;35(1):57.
26. Sudo D, Monobe Y, Yashiro M, Mieno MN, Uehara R, Tsuchiya K, et al. Coronary artery lesions of incomplete Kawasaki disease: a nationwide survey in Japan. *European journal of pediatrics*. 2012;1-6.
27. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease. *Circulation*. 2004;110(17):2747-71.
28. Kusakawa S, Tatara K. Efficacies and risks of aspirin in the treatment of the Kawasaki disease. *Progress in clinical and biological research*. 1987;250:401.
29. Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited. *Pediatrics*. 2004;114(6):e689-e93.
30. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. *New England Journal of Medicine*. 2001;345(25):1809-17.
31. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. *Pediatrics*. 1995;96(6):1057-61.
32. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. *The Journal of pediatrics*. 1997;131(6):888-93.
33. Sundel RP, Baker AL, Fulton DR, Newburger JW. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. *The Journal of pediatrics*. 2003;142(6):611-6.
34. Wooditch AC, Aronoff SC. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children. *Pediatrics*. 2005;116(4):989-95.
35. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. *Pediatrics*. 1979;63(2):175-9.
36. Shinohara M, Sone K, Tomomasa T, Morikawa A. Corticosteroids in the treatment of the acute phase of Kawasaki disease. *The Journal of pediatrics*. 1999;135(4):465-9.
37. Inoue Y, Okada Y, Shinohara M, Kobayashi T, Tomomasa T, Takeuchi K, et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. *The Journal of pediatrics*. 2006;149(3):336-41. e1.
38. Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon- γ in Kawasaki disease involved coronary-artery lesions. *Clinical immunology and immunopathology*. 1990;56(1):29-36.
39. Eberhard BA, Andersson U, Laxer RM, Rose V, Silverman ED. Evaluation of the cytokine response in Kawasaki disease. *The Pediatric infectious disease journal*. 1995;14(3):199.
40. Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, et al. Infliximab treatment for refractory Kawasaki syndrome. *The Journal of pediatrics*. 2005;146(5):662-7.
41. Okada K, Hara J, Maki I, Miki K, Matsuzaki K, Matsuoka T, et al. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. *European journal of pediatrics*. 2009;168(2):181-5.
42. Suzuki H, Terai M, Hamada H, Honda T, Suenaga T, Takeuchi T, et al. Cyclosporin A treatment for Kawasaki disease refractory to initial and additional

- intravenous immunoglobulin. *The Pediatric infectious disease journal*. 2011;30(10):871-6.
43. Kashiwagi Y, Kawashima H, Akamatsu N, Morishima Y, Nishimata S. Efficacy of plasma exchange therapy for Kawasaki disease by cytokine profiling. *Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy*. 2012;16(3):281-3. Epub 2012/05/23.
 44. Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. *Pediatrics*. 2000;105(6):e78-e.
 45. Lee TJ, Kim KH, Chun JK, Kim DS. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease. *Yonsei medical journal*. 2008;49(5):714-8.
 46. Miura M, Tamame T, Naganuma T, Chinen S, Matsuoka M, Ohki H. Steroid pulse therapy for Kawasaki disease unresponsive to additional immunoglobulin therapy. *Paediatrics & Child Health*. 2011;16(8):479.
 47. Mitani Y, Sawada H, Hayakawa H, Aoki K, Ohashi H, Matsumura M, et al. Elevated levels of high-sensitivity C-reactive protein and serum amyloid-A late after Kawasaki disease. *Circulation*. 2005;111(1):38-43.
 48. Sleeper LA, Minich LLA, McCrindle BM, Li JS, Mason W, Colan SD, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. *The Journal of pediatrics*. 2011;158(5):831-5. e3.
 49. Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. *The Journal of pediatrics*. 2006;149(2):237-40.
 50. Kuo HC, Liang CD, Wang CL, Yu HR, Hwang KP, Yang KD. Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease. *Acta Paediatrica*. 2010;99(10):1578-83.
 51. Kuo HC, Yang KD, Liang CD, Bong CN, Yu HR, Wang L, et al. The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease. *Pediatric allergy and immunology*. 2007;18(4):354-9.
 52. Rigante D, Valentini P, Rizzo D, Leo A, De Rosa G, Onesimo R, et al. Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome. *Rheumatology international*. 2010;30(6):841-6.
 53. Do YS, Kim KW, Chun JK, Cha BH, Namgoong MK, Lee HY. Predicting factors for refractory Kawasaki disease. *Korean circulation journal*. 2010;40(5):239-42.
 54. Ashouri N, Takahashi M, Dorey F, Mason W. Risk factors for nonresponse to therapy in Kawasaki disease. *The Journal of pediatrics*. 2008;153(3):365-8.
 55. Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. *European journal of pediatrics*. 2007;166(2):131-7.
 56. Nakano H, Ueda K, Saito A, Tsuchitani Y, Kawamori J, Miyake T, et al. Scoring method for identifying patients with Kawasaki disease at high risk of coronary artery aneurysms. *The American journal of cardiology*. 1986;58(9):739-42.
 57. Hashino K, Ishii M, Iemura M, Akagi T, Kato H. Re-treatment for immune globulin-resistant Kawasaki disease: A comparative study of additional immune globulin and steroid pulse therapy. *Pediatrics International*. 2001;43(3):211-7.
 58. Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. *The Lancet*. 2012.
 59. Ogata S, Bando Y, Kimura S, Ando H, Nakahata Y, Ogihara Y, et al. The strategy of immune globulin resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. *Journal of cardiology*. 2009;53(1):15-9.
 60. Tremoulet AH, Pancoast P, Franco A, Bujold M, Shimizu C, Onouchi Y, et al. Calcineurin Inhibitor Treatment of Intravenous Immunoglobulin-Resistant Kawasaki Disease. *The Journal of pediatrics*. 2012.
 61. Choueiter NF, Olson AK, Shen DD, Portman MA. Prospective open-label trial of etanercept as adjunctive therapy for Kawasaki disease. *The Journal of pediatrics*. 2010;157(6):960-6. e1.
 62. Girish M, Subramaniam G. Infliximab treatment in refractory Kawasaki syndrome. *Indian journal of pediatrics*. 2008;75(5):521-2.